Akers Biosciences, Inc. Issue of Equity & Directors' Shareholdings (5058K)
December 31 2015 - 2:00AM
UK Regulatory
TIDMAKR
RNS Number : 5058K
Akers Biosciences, Inc.
31 December 2015
Akers Biosciences, Inc.
Issue of Equity & Directors' Shareholdings
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company"), a leading designer and manufacturer of rapid diagnostic
screening and testing products, announces that, pursuant to the
Company's 2013 Incentive Stock and Award Plan, as amended, the
Company has allocated for issuance an aggregate of 280,208 shares
of the Company's restricted common stock, of no par value per share
("Restricted Stock") for nil consideration. The Restricted Stock is
to be issued to certain officers and directors (the "Grantees") for
services rendered to the Company.
As a result of the allocation of Restricted Stock, the Company
sets out below the changes in the directors' interests in the
Company:
Director Number of Number of Number Percentage
Common Shares shares held of Stock of total
held prior after the Options outstanding
to the allocation allocation held shares (excluding
of Restricted of Restricted unexercised
Stock Stock Stock Options)
Thomas J.
Knox 408,150 478,150 20,000 8.81 %
Brandon
Knox 83,076 138,076 20,000 2.55 %
Robert Andrews - 48,125 - 0.89 %
Raza Bokhari - 32,083 - 0.59 %
Application has been made for the 280,208 Restricted Stock
shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will take place on 7 January 2016.
The new Restricted Stock will rank pari passu with the existing
shares of the Company. Subsequent to Admission, the total number of
issued ordinary shares will be 5,425,045. There are no ordinary
shares held in treasury and so the total number of voting rights in
the Company will be 5,425,045.
The above figures may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company under the Financial Conduct Authority's Disclosure
and Transparency Rules.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEANAEDDLSFFF
(END) Dow Jones Newswires
December 31, 2015 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024